Alembic receives FDA nod for generic Corlanor
Ivabradine is indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction.
The Food and Drug Administration has given Alembic permission for Ivabradine tablets, 5 mg and 7.5 mg, which is the generic of Amgen’s Corlanor.
Ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction.
[Read more: Alembic intros generic Perforomist]
Ivabradine tablets, 5 mg and 7.5 mg have a market size of $145.3 million for the 12 months ending September 2024, per IQVIA.
[Read more: Alembic releases generic Pradaxa]